PL2074108T3 - Inhibitory reniny - Google Patents

Inhibitory reniny

Info

Publication number
PL2074108T3
PL2074108T3 PL07838381T PL07838381T PL2074108T3 PL 2074108 T3 PL2074108 T3 PL 2074108T3 PL 07838381 T PL07838381 T PL 07838381T PL 07838381 T PL07838381 T PL 07838381T PL 2074108 T3 PL2074108 T3 PL 2074108T3
Authority
PL
Poland
Prior art keywords
renin inhibitors
renin
inhibitors
Prior art date
Application number
PL07838381T
Other languages
English (en)
Other versions
PL2074108T6 (pl
Inventor
John J Baldwin
David A Claremon
Colin M Tice
Salvacion Cacatian
Lawrence W Dillard
Alexey V Ishchenko
Jing Yuan
Zhenrong Xu
Gerard Mcgeehan
Wei Zhao
Robert D Simpson
Suresh B Singh
Lanqi Jia
Patrick T Flaherty
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786973&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2074108(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of PL2074108T3 publication Critical patent/PL2074108T3/pl
Publication of PL2074108T6 publication Critical patent/PL2074108T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL07838381T 2006-09-18 2007-09-18 Inhibitory reniny PL2074108T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84529106P 2006-09-18 2006-09-18
PCT/US2007/020164 WO2008036247A1 (en) 2006-09-18 2007-09-18 Renin inhibitors
EP07838381.7A EP2074108B3 (en) 2006-09-18 2007-09-18 Renin inhibitors

Publications (2)

Publication Number Publication Date
PL2074108T3 true PL2074108T3 (pl) 2013-05-31
PL2074108T6 PL2074108T6 (pl) 2013-11-29

Family

ID=38786973

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07838381T PL2074108T6 (pl) 2006-09-18 2007-09-18 Inhibitory reniny

Country Status (22)

Country Link
US (2) US8198453B2 (pl)
EP (2) EP2581366A1 (pl)
JP (1) JP5331695B2 (pl)
KR (1) KR20090064582A (pl)
CN (1) CN101528723B (pl)
AR (1) AR062797A1 (pl)
AU (1) AU2007297729C1 (pl)
BR (1) BRPI0718460A2 (pl)
CA (1) CA2663263A1 (pl)
CL (1) CL2007002689A1 (pl)
DK (1) DK2074108T3 (pl)
ES (1) ES2400009T7 (pl)
HR (1) HRP20130144T4 (pl)
MX (1) MX2009002740A (pl)
NZ (1) NZ575803A (pl)
PE (1) PE20080843A1 (pl)
PL (1) PL2074108T6 (pl)
PT (1) PT2074108E (pl)
RS (1) RS52679B (pl)
SI (1) SI2074108T1 (pl)
TW (1) TWI403510B (pl)
WO (1) WO2008036247A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003858A (es) 2004-10-07 2007-12-11 Vitae Pharmaceuticals Inc Diaminoalcanos inhibidores de proteasa asparticas.
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
ATE520690T1 (de) * 2006-09-18 2011-09-15 Vitae Pharmaceuticals Inc Piperidinderivate als renin-inhibitoren
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2008156817A2 (en) * 2007-06-20 2008-12-24 Vitae Pharmaceuticals, Inc. Renin inhibitors
WO2009096996A1 (en) * 2007-06-20 2009-08-06 Smithkline Beecham Corporation Renin inhibitors
WO2009154766A1 (en) * 2008-06-20 2009-12-23 Vitae Pharmaceuticals, Inc. Renin inhibitors and method of use thereof
US20100010228A1 (en) * 2008-06-26 2010-01-14 Vitae Pharmaceuticals, Inc. Process for the asymmetric reduction of 3-benzoylpiperidines
EP2306826A4 (en) * 2008-06-26 2011-07-27 Vitae Pharmaceuticals Inc SALTS OF METHYL-2 - ((R)) - (3-CHLOROPHENYL) ((R) 1 - ((S) -2- (METHYLAMINO) -3 ((R) -TETRAHYDRO-2H-PYRAN-3-YL) propylcarbamoyl) piperidin-3-yl) methoxy) ETHYL CARBAMATE
DK2413902T3 (da) 2009-03-18 2019-10-07 Incarda Therapeutics Inc Enhedsdoser, aerosoler, kits og fremgangsmåder til behandling af hjertetilstande ved pulmonal indgivelse
AU2013248242B2 (en) * 2009-03-18 2016-08-18 Incarda Therapeutics, Inc Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2016256776B2 (en) * 2009-03-18 2018-04-12 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AR077692A1 (es) * 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
SG10202012584UA (en) 2016-02-01 2021-01-28 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3768378B1 (en) 2018-03-22 2025-08-06 InCarda Therapeutics, Inc. A novel method to slow ventricular rate
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
IL290088B2 (en) 2019-08-01 2023-10-01 Incarda Therapeutics Inc A pharmaceutical preparation containing flacainide, cyclodextrin and acid, a dosage unit of the preparation and a kit containing the preparation
CN117567292B (zh) * 2023-12-01 2026-01-16 江苏宝众宝达药业股份有限公司 一种制备高纯度5-氯-2-甲基苯胺的方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3071618A (en) 1956-02-02 1963-01-01 Pfizer & Co C Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
JPS5115098A (ja) 1974-07-26 1976-02-06 Asahi Chemical Ind Akurirukeiseniseihinno shorihoho
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en) 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
HU227346B1 (en) 1990-05-11 2011-04-28 Pfizer Process for producing synergetic pharmaceutical composition
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
DE4018070A1 (de) 1990-06-06 1991-12-12 Bayer Ag Morpholinoharnstoff-derivate
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
FI932687A7 (fi) 1990-12-14 1993-06-11 Merrell Dow Pharma Allergianvastaisia yhdisteitä
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2129995C (en) 1992-02-13 2000-04-11 Albert A. Carr Piperidinyl thiacyclic derivatives
ES2101323T3 (es) 1992-06-10 1997-07-01 Nanosystems Llc Nanoparticulas de farmacos antiinflamatorios no esteroideos (nsaid) con superficie modificada.
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
WO1996004232A1 (en) 1994-07-29 1996-02-15 Abbott Laboratories Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
AU7697298A (en) 1997-05-29 1998-12-30 Eli Lilly And Company Process for preparing heterocyclic compounds
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) * 1998-12-02 1999-01-27 Darwin Discovery Ltd Process
US6613764B1 (en) 1999-01-06 2003-09-02 The United States Of America As Represented By The Department Of Health And Human Services Aspartic protease inhibitors
JP2000302757A (ja) 1999-04-16 2000-10-31 Shiseido Co Ltd Ｎ−置換ピペリジン誘導体
HUP0300068A2 (en) 2000-03-21 2003-05-28 Smithkline Beecham Corp Protease inhibitors, their preparation, their use and pharmaceutical compositions containing them
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
HRP20040069A2 (en) 2001-07-11 2005-02-28 Elan Pharmaceuticals Pharmacia & Upjohn Company N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
EP1453789A2 (en) 2001-11-08 2004-09-08 Elan Pharmaceuticals, Inc. N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2003090691A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
AU2003238046A1 (en) 2002-06-27 2004-01-19 Actelion Pharmaceuticals Ltd Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
AU2003273310A1 (en) 2002-09-10 2004-04-30 Pharmacia And Upjohn Substituted aminoethers for the treatment of alzheimer's disease
JP2007509898A (ja) 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
US20070093492A1 (en) 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
WO2006023844A2 (en) 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
MX2007003858A (es) 2004-10-07 2007-12-11 Vitae Pharmaceuticals Inc Diaminoalcanos inhibidores de proteasa asparticas.
RU2007132438A (ru) * 2005-01-28 2009-03-10 Актелион Фармасьютикалз Лтд (Ch) Циклопропил-(2,3-диметилбензил)амид 7-{4-[2-(2,6-дихлор-4-метилфенокси)этокси]фенил}-3,9-диазабицикло[3.3.1]нон-6-ен-6-карбоновой кислоты в качестве ингибиторов ренина для лечения артериальной гипертензии
EP1844002A1 (en) * 2005-02-02 2007-10-17 Vitae Pharmaceuticals, Inc. 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
CA2608957C (en) 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
WO2007117557A2 (en) 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
ATE520690T1 (de) 2006-09-18 2011-09-15 Vitae Pharmaceuticals Inc Piperidinderivate als renin-inhibitoren
WO2008156817A2 (en) 2007-06-20 2008-12-24 Vitae Pharmaceuticals, Inc. Renin inhibitors
WO2009096996A1 (en) 2007-06-20 2009-08-06 Smithkline Beecham Corporation Renin inhibitors
US7773441B2 (en) * 2008-06-18 2010-08-10 Micron Technology, Inc. Memory malfunction prediction system and method
WO2009154766A1 (en) 2008-06-20 2009-12-23 Vitae Pharmaceuticals, Inc. Renin inhibitors and method of use thereof
EP2306826A4 (en) 2008-06-26 2011-07-27 Vitae Pharmaceuticals Inc SALTS OF METHYL-2 - ((R)) - (3-CHLOROPHENYL) ((R) 1 - ((S) -2- (METHYLAMINO) -3 ((R) -TETRAHYDRO-2H-PYRAN-3-YL) propylcarbamoyl) piperidin-3-yl) methoxy) ETHYL CARBAMATE
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

Also Published As

Publication number Publication date
HRP20130144T1 (en) 2013-03-31
ES2400009T7 (es) 2013-11-18
EP2074108B1 (en) 2012-11-21
CN101528723B (zh) 2013-04-10
EP2074108B3 (en) 2013-06-26
MX2009002740A (es) 2009-06-26
HK1129115A1 (en) 2009-11-20
JP2010503684A (ja) 2010-02-04
PL2074108T6 (pl) 2013-11-29
US20120225906A1 (en) 2012-09-06
DK2074108T3 (da) 2013-03-11
RS52679B (sr) 2013-06-28
CN101528723A (zh) 2009-09-09
ES2400009T3 (es) 2013-04-05
CL2007002689A1 (es) 2008-04-18
AU2007297729C1 (en) 2012-02-02
WO2008036247A1 (en) 2008-03-27
PT2074108E (pt) 2013-03-07
WO2008036247A8 (en) 2008-06-26
AR062797A1 (es) 2008-12-03
US8198453B2 (en) 2012-06-12
US8580823B2 (en) 2013-11-12
EP2581366A1 (en) 2013-04-17
KR20090064582A (ko) 2009-06-19
TWI403510B (zh) 2013-08-01
HRP20130144T4 (hr) 2013-10-25
AU2007297729A1 (en) 2008-03-27
EP2074108A1 (en) 2009-07-01
CA2663263A1 (en) 2008-03-27
JP5331695B2 (ja) 2013-10-30
PE20080843A1 (es) 2008-08-11
TW200829574A (en) 2008-07-16
AU2007297729B2 (en) 2011-07-28
US20090312369A1 (en) 2009-12-17
BRPI0718460A2 (pt) 2013-12-03
NZ575803A (en) 2011-11-25
SI2074108T1 (sl) 2013-04-30

Similar Documents

Publication Publication Date Title
HRP20130144T1 (en) Renin inhibitors
GB0619753D0 (en) Enzyme inhibitors
PL2361922T3 (pl) Produkty pośrednie do wytwarzania inhibitorów nukleozydowych HCV
PL2402319T3 (pl) Inhibitory DGAT
IL200779A0 (en) Pdgfr beta-specific inhibitors
IL194339A0 (en) Enzyme inhibitors
EP2036894A4 (en) AURORA INHIBITOR
AP2009004784A0 (en) Matrix metallproteinase inhibitors
IL186038A0 (en) Polymeric inhibitors for enhanced planarization
IL193150A0 (en) Secondary amines as renin inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
EP2064177A4 (en) PROTEASE INHIBITORS
ZA200808419B (en) Primary amines as renin inhibitors
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
GB0624187D0 (en) HDAC inhibitors
IL173706A0 (en) Corrosion inhibitors
GB0608844D0 (en) Enzyme inhibitors
GB0617161D0 (en) Enzyme inhibitors
EP2076490A4 (en) INHIBITORS OF CATHEPSIN B
GB0714941D0 (en) Inhibitors
GB0622367D0 (en) Phosphodiesterase inhibitors
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0720364D0 (en) Inhibitor
GB0620884D0 (en) Enzyme inhibitors
ZA200808237B (en) Enzyme inhibitors